N von Hentig

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Safety of pharmacoenhancers for HIV therapy
    Nils von Hentig
    HIVCENTER, Medical Department II, Hospital of the J W Goethe University, Frankfurt, Germany
    Expert Rev Clin Pharmacol 5:557-68. 2012
  2. ncbi Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients
    Nils von Hentig
    Pharmazentrum Frankfurt, Department of Virology, JohannWolfgang Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 12:1237-46. 2007
  3. ncbi Atazanavir/ritonavir: a review of its use in HIV therapy
    Nils von Hentig
    Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Drugs Today (Barc) 44:103-32. 2008
  4. ncbi Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 52:2273-5. 2008
  5. ncbi The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 62:579-82. 2008
  6. ncbi Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 62:1118-21. 2008
  7. ncbi Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Antivir Ther 13:1039-46. 2008
  8. ncbi A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII
    Christoph Konigs
    Molecular Hemostasis and Immunodeficiencies, Department of Paediatrics, Medical Centre of Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Drugs Today (Barc) 45:469-80. 2009
  9. ncbi A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII
    Christoph Konigs
    Molecular Hemostasis and Immunodeficiencies, Department of Paediatrics, Medical Centre of Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Drugs Today (Barc) 45:549-61. 2009
  10. ncbi [Measurement of the plasma concentration of antiretroviral drugs in HIV therapy]
    N von Hentig
    Pharmazentrum Frankfurt / ZAFES, , , Theodor-Stern-Kai 7, 60590 Frankfurt am Main
    Dtsch Med Wochenschr 133:191-5. 2008

Detail Information

Publications31

  1. ncbi Safety of pharmacoenhancers for HIV therapy
    Nils von Hentig
    HIVCENTER, Medical Department II, Hospital of the J W Goethe University, Frankfurt, Germany
    Expert Rev Clin Pharmacol 5:557-68. 2012
    ..This article reviews current literature, compares the safety of both pharmacoenhancers and appraises their use in current and future HIV therapy...
  2. ncbi Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients
    Nils von Hentig
    Pharmazentrum Frankfurt, Department of Virology, JohannWolfgang Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 12:1237-46. 2007
    ..To evaluate predictive factors for therapy outcome of a boosted double-protease inhibitor (PI) regimen in 58 extensively pre-treated patients with HIV...
  3. ncbi Atazanavir/ritonavir: a review of its use in HIV therapy
    Nils von Hentig
    Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Drugs Today (Barc) 44:103-32. 2008
    ..where boosted atazanavir-containing HAART was compared to a regimen with lopinavir/ritonavir in therapy-naive patients...
  4. ncbi Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 52:2273-5. 2008
    ..Therefore, patients should be selected carefully for this regimen and frequent clinical and therapeutic drug monitoring is strongly advised...
  5. ncbi The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 62:579-82. 2008
    ....
  6. ncbi Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 62:1118-21. 2008
    ..Thromboembolic complications under antiretroviral therapy (ART) have been described in the past. In particular, the influence of protease inhibitors (PIs) on platelet activation and coagulation is currently under discussion...
  7. ncbi Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Antivir Ther 13:1039-46. 2008
    ....
  8. ncbi A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII
    Christoph Konigs
    Molecular Hemostasis and Immunodeficiencies, Department of Paediatrics, Medical Centre of Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Drugs Today (Barc) 45:469-80. 2009
    ....
  9. ncbi A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII
    Christoph Konigs
    Molecular Hemostasis and Immunodeficiencies, Department of Paediatrics, Medical Centre of Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Drugs Today (Barc) 45:549-61. 2009
    ....
  10. ncbi [Measurement of the plasma concentration of antiretroviral drugs in HIV therapy]
    N von Hentig
    Pharmazentrum Frankfurt / ZAFES, , , Theodor-Stern-Kai 7, 60590 Frankfurt am Main
    Dtsch Med Wochenschr 133:191-5. 2008
  11. ncbi Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Eur J Clin Pharmacol 63:935-40. 2007
    ..Our objective was to evaluate the steady-state pharmacokinetics of ritonavir-boosted atazanavir when coadministered with tenofovir in HIV-1-infected adult patients...
  12. ncbi Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen
    Nils von Hentig
    Pharmazentrum Frankfurt and HIV Treatment and Clinical Research Unit at the J W Goethe University Hospital, Frankfurt, Germany
    Antimicrob Agents Chemother 51:1431-9. 2007
    ..We conclude that our pharmacokinetic results support the use of a boosted double-PI regimen of ATV/SQV/RTV as a treatment option for patients who need antiretroviral therapy without RTIs...
  13. ncbi Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults
    Nils von Hentig
    Institute for Clinical Pharmacology, J W Goethe University Hospital, Frankfurt, Theodor Stern Kai 7, D 60590 Frankfurt M, Germany
    Eur J Med Res 11:236-44. 2006
    ..The authors evaluated the pharmacokinetics and tolerability of indinavir/lopinavir/ritonavir in a protease inhibitor only combination...
  14. ncbi Lopinavir/ritonavir: appraisal of its use in HIV therapy
    Nils von Hentig
    Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Drugs Today (Barc) 43:221-47. 2007
    ..33 mg), liquid formulation (80/20 mg/ml) and recently approved melt-extrusion tablet (200/50 mg). Lopinavir/ritonavir is recommended for first- and second-line therapy in HIV-1 infection, in children as well as adolescents and adults...
  15. ncbi A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy
    Nils von Hentig
    Pharmazentrum Frankfurt at the JW Goethe University, Frankfurt, Germany
    Br J Clin Pharmacol 62:552-9. 2006
    ....
  16. ncbi Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines
    Nils von Hentig
    Institute for Clinical Pharmacology, Pharmazentrum frankfurt ZAFES, J W Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Eur J Med Res 11:377-80. 2006
    ..Until now little is known about the steady state pharmacokinetics of efavirenz in children...
  17. ncbi Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients
    M Bickel
    HIVCENTER, JW Goethe University Hospital, Theodor Stern Kai 7, Frankfurt, Germany
    J Antimicrob Chemother 64:1260-4. 2009
    ..To investigate the feasibility and pharmacokinetics of a once-daily regimen of 2000 mg saquinavir mesylate boosted with 100 mg ritonavir...
  18. ncbi Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children
    Markus B Funk
    Children s Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany
    Eur J Med Res 10:503-8. 2005
    ..In an intent-to-treat study, reduction of viral load, increase in CD4 cell count, clinical benefit and adverse reactions were examined in HIV-infected children receiving first line therapy including efavirenz...
  19. ncbi Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
    Christoph Stephan
    Division of Infectious Disease, and Institute of Clinical Pharmacology, Pharma Center, JW Goethe University Hospital, Frankfurt, Germany
    AIDS 18:503-8. 2004
    ..To assess the pharmacokinetic interaction of saquinavir and lopinavir/ritonavir...
  20. ncbi Dose reduction effective in alleviating symptoms of saquinavir toxicity
    C Stephan
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Department of Internal Medicine II, Frankfurt, Germany
    Int J STD AIDS 18:81-4. 2007
    ..Although delayed autoinduction is not well established as a reason for adverse events in saquinavir therapy, this observation may be confirmed in the near future by increased use...
  21. ncbi Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
    Annette Haberl
    HIVCENTER, Medical Clinics II, J W Goethe University Hospital, Frankfurt am Main, Germany
    Eur J Clin Pharmacol 66:375-81. 2010
    ..We performed a matched-pairs analysis on 24 patients (12 men/women) taking atazanavir/ritonavir 300/100 mg daily plus reverse transcriptase inhibitors, with (n = 12) or without (n = 12) methadone co-administration...
  22. ncbi Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 53:3524-7. 2009
    ..In contrast, age, sex, weight, pregnancy, and the pharmaceutical formulation exerted only minor, nonsignificant effects...
  23. ncbi Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Pharmacogenet Genomics 19:429-36. 2009
    ..We analyzed the imprint of these variants in opioid therapy in a highly variable cohort of pain patients treated in outpatient units to test whether genotyping may play a role in this clinical setting...
  24. ncbi Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 51:3264-72. 2007
    ..It may be contemplated in cases with constitutional side effects or low CD4 counts with weak immune responses...
  25. ncbi Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time
    Sebastian Harder
    Pharmazentrum Frankfurt, Institute for Clinical Pharmacology, University Hospital, Frankfurt am Main, Germany
    Thromb Haemost 91:1137-45. 2004
    ..2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced by VKA can be used as an alternative to the aPTT...
  26. ncbi Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir
    Markus Bickel
    HIVCENTER, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    J Antimicrob Chemother 65:999-1004. 2010
    ..The introduction of raltegravir, which is not metabolized by the cytochrome system, may allow concomitant treatment without dose adaptation...
  27. ncbi Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    Inflamm Res 59:989-95. 2010
    ..To evaluate whether non-opioid antipyretic analgesics are associated with lower pain scores, opioid doses and side effects in pain patients in tertiary care...
  28. ncbi Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
    Jochen Graff
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, University Hospital, Frankfurt Main, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    J Clin Pharmacol 47:1398-407. 2007
    ..Rivaroxaban strongly inhibits platelet-induced thrombin generation, after activation of either platelets or the coagulation pathway, even in the presence of minimal factor Xa inhibition in plasma...
  29. ncbi Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo
    Jochen Graff
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology at the Johann Wolfgang Goethe University Frankfurt, Germany
    J Antimicrob Chemother 61:394-9. 2008
    ..Recently, the FDA published a warning concerning intracranial haemorrhage in patients taking the HIV-1 protease inhibitor tipranavir co-administered with ritonavir...
  30. ncbi Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study
    Inmaculada Martinez-Saguer
    Centre of Paediatrics III, Department of Haematology, Oncology and Haemostasis, Comprehensive Care Centre for Thrombosis and Haemostasis, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Transfusion 50:354-60. 2010
    ..This pharmacokinetic study was conducted to investigate the pharmacokinetics of pasteurized human plasma-derived C1-INH concentrate (pC1-INH)...
  31. ncbi Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Frankfurt, Germany
    AIDS 24:F31-5. 2010
    ..To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172)...